Henry Schein (NASDAQ:HSIC – Get Free Report) and Precipio (NASDAQ:PRPO – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.
Profitability
This table compares Henry Schein and Precipio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Henry Schein | 2.96% | 15.97% | 5.56% |
| Precipio | -4.47% | -8.49% | -5.75% |
Analyst Ratings
This is a breakdown of current recommendations and price targets for Henry Schein and Precipio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Henry Schein | 1 | 5 | 9 | 0 | 2.53 |
| Precipio | 1 | 0 | 0 | 0 | 1.00 |
Volatility & Risk
Henry Schein has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Precipio has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500.
Institutional & Insider Ownership
96.6% of Henry Schein shares are owned by institutional investors. Comparatively, 10.4% of Precipio shares are owned by institutional investors. 0.9% of Henry Schein shares are owned by company insiders. Comparatively, 16.6% of Precipio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Henry Schein and Precipio”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Henry Schein | $13.18 billion | 0.75 | $398.00 million | $3.43 | 25.77 |
| Precipio | $24.05 million | 1.99 | -$360,000.00 | ($0.64) | -41.81 |
Henry Schein has higher revenue and earnings than Precipio. Precipio is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks.
Summary
Henry Schein beats Precipio on 11 of the 14 factors compared between the two stocks.
About Henry Schein
Henry Schein, Inc. provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products, such as branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners; and value-added practice solutions comprising practice consultancy, education, revenue cycle management and financial services, e-services, practice technology, and network and hardware services, as well as consulting, and continuing education services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
About Precipio
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
